Compounding Pharmacy Formulary — 503A & 503B Peptide Access
Every product sourced exclusively from state-licensed 503A and 503B compounding pharmacies using pharmaceutical-grade active pharmaceutical ingredients. Only what is currently legal to compound — updated in real time.
Quality Without Compromise
Every compound sourced exclusively from state-licensed 503A and 503B pharmacies. Only what is currently legal to compound — updated in real time as regulations change.
FDA-Registered Pharmacies
Every partner pharmacy holds active FDA registration and state-specific compounding licenses. No grey-market sourcing, ever.
CoA for Every Lot
Certificate of Analysis accompanies every shipment — potency, purity, sterility, and endotoxin testing verified before release.
Real-Time Compliance
Formulary updates automatically when FDA bulk substance classifications change — your practice stays compliant and current.
Available Compounds
GLP-1 & Metabolic Agents
Semaglutide (GLP-1) — Subject to FDA shortage status
GLP-1 Receptor Agonist
A glucagon-like peptide-1 receptor agonist prescribed for chronic weight management. Mimics the incretin hormone GLP-1 to regulate appetite, slow gastric emptying, and support sustained weight loss in conjunction with lifestyle modification.
Route: Subcutaneous Injection
Tirzepatide (GLP-1/GIP) — Subject to FDA shortage status
Dual Incretin Agonist
A dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist offering enhanced metabolic response. Targets two incretin pathways simultaneously, offering enhanced metabolic support through dual-pathway activation.
Route: Subcutaneous Injection
Cellular Optimization
NAD+
Nicotinamide Adenine Dinucleotide
A critical coenzyme present in every cell, essential for cellular energy production, DNA repair, and mitochondrial function. Supports cellular health and longevity pathways, cognitive clarity, and metabolic health through direct cofactor replenishment.
Route: IV Infusion or Subcutaneous
Glutathione IV
Master Antioxidant
The body's most powerful endogenous antioxidant, delivered intravenously for maximum bioavailability. Supports detoxification pathways, reduces oxidative stress, may support skin health and appearance, and enhances liver function and immune resilience.
Route: IV Push
Methylcobalamin B12
Active Vitamin B12
The bioactive, methylated form of vitamin B12 essential for neurological function, red blood cell formation, and energy metabolism. Superior to cyanocobalamin for direct cellular utilization without requiring hepatic conversion.
Route: IM Injection
Growth Hormone Optimization
Sermorelin
GHRH Analog
A growth hormone releasing hormone analog that stimulates the pituitary gland to produce and secrete growth hormone naturally. Supports anti-aging, improved body composition, deeper sleep quality, and accelerated tissue recovery.
Route: Subcutaneous Injection
Targeted Therapeutics
PT-141 / Bremelanotide
Melanocortin Receptor Agonist
A melanocortin receptor agonist that acts on the central nervous system to support sexual wellness. Works through neurological pathways rather than vascular mechanisms, offering a distinct approach for both male and female patients. FDA-approved as Vyleesi — legal to compound as a component of an FDA-approved drug.
Route: Subcutaneous Injection
Metabolic Support
MIC / Lipo-B Injections
Lipotropic Compounds
A combination of methionine, inositol, choline, and B-vitamins designed to support fat metabolism and liver function. Enhances the body's ability to metabolize lipids, supports energy levels, and complements weight management protocols.
Route: IM Injection
Unavailable Compounds
The following compounds cannot currently be legally compounded. Some are FDA Category 2 (bulk drug substances that raise significant safety concerns), while others were removed from Category 2 but subsequently rejected by the Pharmacy Compounding Advisory Committee (PCAC). We continue to monitor regulatory developments. HHS Secretary RFK Jr. has announced plans to reclassify several of these peptides to Category 1 (JRE #2461, Feb 27, 2026). Members will be notified immediately when reclassifications take effect.
BPC-157
Body Protection Compound
A synthetic peptide derived from gastric juice proteins, previously used for tissue repair and gastrointestinal support. Currently classified as FDA Category 2 — cannot be legally compounded. RFK Jr. announced plans to reclassify to Category 1 on JRE #2461 (Feb 27, 2026).
Status: Unavailable — FDA Category 2
TB-500 (Thymosin Beta-4)
Tissue Repair Peptide
A naturally occurring peptide involved in tissue repair, cell migration, and angiogenesis. Currently classified as FDA Category 2 — cannot be legally compounded. RFK Jr. announced plans to reclassify to Category 1 on JRE #2461 (Feb 27, 2026).
Status: Unavailable — FDA Category 2
DSIP (Emideltide)
Delta Sleep-Inducing Peptide
A neuropeptide involved in the regulation of sleep architecture, specifically promoting delta wave (deep) sleep. Currently classified as FDA Category 2 — cannot be legally compounded. RFK Jr. announced plans to reclassify to Category 1 on JRE #2461 (Feb 27, 2026).
Status: Unavailable — FDA Category 2
GHK-Cu (Injectable)
Copper Peptide
A copper-binding tripeptide marketed for anti-aging and tissue repair. Injectable forms are classified as FDA Category 2 — cannot be legally compounded. Topical (non-injectable) GHK-Cu remains available for compounding.
Status: Unavailable — FDA Category 2 (Injectable Only)
LL-37 (Cathelicidin)
Antimicrobial Peptide
A host defense peptide with antimicrobial and immune-modulating properties. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
Dihexa Acetate
Cognitive Enhancement Peptide
A peptide marketed for cognitive enhancement and neuroprotection. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
Epithalon
Telomerase Activator
A tetrapeptide marketed for telomere extension and anti-aging. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
MK-677 (Ibutamoren Mesylate)
GH Secretagogue
A non-peptide growth hormone secretagogue marketed for GH release and muscle growth. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
Kisspeptin-10
Reproductive Hormone Modulator
A neuropeptide involved in reproductive hormone signaling and GnRH regulation. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
KPV
Anti-Inflammatory Tripeptide
A tripeptide fragment of alpha-MSH marketed for anti-inflammatory and gut health applications. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
Melanotan II
Melanocortin Agonist
A synthetic melanocortin peptide marketed for tanning and sexual dysfunction. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
PEG-MGF
Mechano Growth Factor
A PEGylated variant of mechano growth factor marketed for muscle growth and recovery. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
MOTS-C
Mitochondrial Peptide
A mitochondrial-derived peptide marketed for metabolic regulation and exercise performance. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
Semax
Neuropeptide
A synthetic peptide derived from ACTH marketed for cognitive enhancement and neuroprotection. Currently classified as FDA Category 2 — cannot be legally compounded.
Status: Unavailable — FDA Category 2
Selank (TP-7)
Anxiolytic Neuropeptide
A synthetic peptide derived from tuftsin, marketed for anxiety reduction, cognitive enhancement, and immune modulation. Removed from Category 2 in September 2024 but referred to PCAC — cannot be legally compounded at this time. RFK Jr. announced plans to reclassify to Category 1 on JRE #2461 (Feb 27, 2026).
Status: Unavailable — PCAC Limbo
Thymosin Alpha-1
Immune Modulation Peptide
A naturally occurring thymic peptide that modulates and enhances immune system function. Removed from Category 2 but rejected by the Pharmacy Compounding Advisory Committee (PCAC) on Dec 4, 2024 — cannot be legally compounded at this time. RFK Jr. announced plans to reclassify to Category 1 on JRE #2461 (Feb 27, 2026).
Status: Unavailable — PCAC Rejected
Ipamorelin / CJC-1295
Growth Hormone Secretagogue Combination
A synergistic peptide combination — Ipamorelin as a selective GH secretagogue with CJC-1295 as a GHRH analog. Removed from Category 2 but both rejected by the Pharmacy Compounding Advisory Committee (PCAC) in Oct–Dec 2024 — cannot be legally compounded at this time. RFK Jr. announced plans to reclassify to Category 1 on JRE #2461 (Feb 27, 2026).
Status: Unavailable — PCAC Rejected
AOD-9604
Anti-Obesity Peptide Fragment
A modified fragment of human growth hormone (hGH 176-191) marketed for fat metabolism and weight loss. Removed from Category 2 but rejected by the Pharmacy Compounding Advisory Committee (PCAC) on Dec 4, 2024 — cannot be legally compounded at this time.
Status: Unavailable — PCAC Rejected
A Living Formulary
Our formulary is dynamic — not static. Compound availability is updated in real time as FDA bulk substance classifications change. When a product is added or removed, every Ventra member is notified immediately with updated guidance, compliance documentation, and alternative recommendations.
Ventra's compliance team actively monitors the FDA, state pharmacy boards, and the National Association of Boards of Pharmacy (NABP) to ensure that every compound we offer meets current federal and state regulations. Your practice stays compliant — we handle the regulatory complexity.
See a compound you want to offer?
Join Ventra Wellness to access our full formulary at competitive pharmacy pricing — with pharmacy sourcing, compliance support, and clinical protocols included. Discover why these compounds are transforming practices.